Nuvalent Announced Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial Of NVL-655 Demonstrated Activity In Heavily Pre-Treated Patients With ALK-Positive NSCLC And ALK-Selective, TRK-Sparing Safety Profile
Portfolio Pulse from Benzinga Newsdesk
Nuvalent has announced preliminary Phase 1 dose-escalation data from its ALKOVE-1 trial of NVL-655, demonstrating activity in heavily pre-treated patients with ALK-positive NSCLC and an ALK-selective, TRK-sparing safety profile. The updated preliminary data will be presented at the 35th AACR-NCI-EORTC Symposium. The company plans to host a conference call on October 13, 2023.
October 04, 2023 | 4:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nuvalent's preliminary Phase 1 data from its ALKOVE-1 trial of NVL-655 shows promising results, which could potentially boost investor confidence in the company.
The announcement of positive preliminary Phase 1 data from Nuvalent's ALKOVE-1 trial of NVL-655 indicates progress in the company's product development. This could potentially boost investor confidence in the company and its future prospects, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100